Phenotypic and molecular detection of CTX-M-β-lactamases produced by Escherichia coli and Klebsiella spp.

Johann D D Pitout, Ashfaque Hossain, Nancy D. Hanson

Research output: Contribution to journalArticle

197 Citations (Scopus)

Abstract

Organisms producing CTX-M-β-lactamases are emerging around the world as a source of resistance to oxyiminocephalosporins such as cefotaxime (CTX). However, the laboratory detection of these strains is not well defined. In this study, a molecular detection assay for the identification of CTX-M-β-lactamase genes was developed and used to investigate the prevalence of these enzymes among clinical isolates of Escherichia coli and Klebsiella species in the Calgary Health Region during 2000 to 2002. In addition, National Committee for Clinical Laboratory Standards (NCCLS) recommendations were evaluated for the ability to detect isolates with CTX-M extended-spectrum β-lactamases (ESBLs). The PCR assay consisted of four primer sets and demonstrated 100% specificity and sensitivity for detecting different groups of CTX-M-β-lactamases in control strains producing well-characterized ESBLs. Using these primer sets, 175 clinical strains producing ESBLs were examined for the presence of CTX-M enzymes; 24 (14%) were positive for blaCTX-M-1-like genes, 95 (54%) were positive for blaCTX-M-14-like genes, and the remaining 56 (32%) were negative for blaCTX-M genes. Following the NCCLS recommendations for ESBL testing, all of the control and clinical strains were detected when screened with cefpodoxime and when both cefotaxime and ceftazidime with clavulanate were used as confirmation tests.

Original languageEnglish
Pages (from-to)5715-5721
Number of pages7
JournalJournal of Clinical Microbiology
Volume42
Issue number12
DOIs
StatePublished - Dec 2004

Fingerprint

Klebsiella
Cefotaxime
Escherichia coli
cefpodoxime
Genes
Clavulanic Acid
Ceftazidime
Enzymes
Sensitivity and Specificity
Polymerase Chain Reaction
Health

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Microbiology

Cite this

Phenotypic and molecular detection of CTX-M-β-lactamases produced by Escherichia coli and Klebsiella spp. / Pitout, Johann D D; Hossain, Ashfaque; Hanson, Nancy D.

In: Journal of Clinical Microbiology, Vol. 42, No. 12, 12.2004, p. 5715-5721.

Research output: Contribution to journalArticle

@article{6fbf79b8a22248fbb58389eff08241be,
title = "Phenotypic and molecular detection of CTX-M-β-lactamases produced by Escherichia coli and Klebsiella spp.",
abstract = "Organisms producing CTX-M-β-lactamases are emerging around the world as a source of resistance to oxyiminocephalosporins such as cefotaxime (CTX). However, the laboratory detection of these strains is not well defined. In this study, a molecular detection assay for the identification of CTX-M-β-lactamase genes was developed and used to investigate the prevalence of these enzymes among clinical isolates of Escherichia coli and Klebsiella species in the Calgary Health Region during 2000 to 2002. In addition, National Committee for Clinical Laboratory Standards (NCCLS) recommendations were evaluated for the ability to detect isolates with CTX-M extended-spectrum β-lactamases (ESBLs). The PCR assay consisted of four primer sets and demonstrated 100{\%} specificity and sensitivity for detecting different groups of CTX-M-β-lactamases in control strains producing well-characterized ESBLs. Using these primer sets, 175 clinical strains producing ESBLs were examined for the presence of CTX-M enzymes; 24 (14{\%}) were positive for blaCTX-M-1-like genes, 95 (54{\%}) were positive for blaCTX-M-14-like genes, and the remaining 56 (32{\%}) were negative for blaCTX-M genes. Following the NCCLS recommendations for ESBL testing, all of the control and clinical strains were detected when screened with cefpodoxime and when both cefotaxime and ceftazidime with clavulanate were used as confirmation tests.",
author = "Pitout, {Johann D D} and Ashfaque Hossain and Hanson, {Nancy D.}",
year = "2004",
month = "12",
doi = "10.1128/JCM.42.12.5715-5721.2004",
language = "English",
volume = "42",
pages = "5715--5721",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Phenotypic and molecular detection of CTX-M-β-lactamases produced by Escherichia coli and Klebsiella spp.

AU - Pitout, Johann D D

AU - Hossain, Ashfaque

AU - Hanson, Nancy D.

PY - 2004/12

Y1 - 2004/12

N2 - Organisms producing CTX-M-β-lactamases are emerging around the world as a source of resistance to oxyiminocephalosporins such as cefotaxime (CTX). However, the laboratory detection of these strains is not well defined. In this study, a molecular detection assay for the identification of CTX-M-β-lactamase genes was developed and used to investigate the prevalence of these enzymes among clinical isolates of Escherichia coli and Klebsiella species in the Calgary Health Region during 2000 to 2002. In addition, National Committee for Clinical Laboratory Standards (NCCLS) recommendations were evaluated for the ability to detect isolates with CTX-M extended-spectrum β-lactamases (ESBLs). The PCR assay consisted of four primer sets and demonstrated 100% specificity and sensitivity for detecting different groups of CTX-M-β-lactamases in control strains producing well-characterized ESBLs. Using these primer sets, 175 clinical strains producing ESBLs were examined for the presence of CTX-M enzymes; 24 (14%) were positive for blaCTX-M-1-like genes, 95 (54%) were positive for blaCTX-M-14-like genes, and the remaining 56 (32%) were negative for blaCTX-M genes. Following the NCCLS recommendations for ESBL testing, all of the control and clinical strains were detected when screened with cefpodoxime and when both cefotaxime and ceftazidime with clavulanate were used as confirmation tests.

AB - Organisms producing CTX-M-β-lactamases are emerging around the world as a source of resistance to oxyiminocephalosporins such as cefotaxime (CTX). However, the laboratory detection of these strains is not well defined. In this study, a molecular detection assay for the identification of CTX-M-β-lactamase genes was developed and used to investigate the prevalence of these enzymes among clinical isolates of Escherichia coli and Klebsiella species in the Calgary Health Region during 2000 to 2002. In addition, National Committee for Clinical Laboratory Standards (NCCLS) recommendations were evaluated for the ability to detect isolates with CTX-M extended-spectrum β-lactamases (ESBLs). The PCR assay consisted of four primer sets and demonstrated 100% specificity and sensitivity for detecting different groups of CTX-M-β-lactamases in control strains producing well-characterized ESBLs. Using these primer sets, 175 clinical strains producing ESBLs were examined for the presence of CTX-M enzymes; 24 (14%) were positive for blaCTX-M-1-like genes, 95 (54%) were positive for blaCTX-M-14-like genes, and the remaining 56 (32%) were negative for blaCTX-M genes. Following the NCCLS recommendations for ESBL testing, all of the control and clinical strains were detected when screened with cefpodoxime and when both cefotaxime and ceftazidime with clavulanate were used as confirmation tests.

UR - http://www.scopus.com/inward/record.url?scp=10844246203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10844246203&partnerID=8YFLogxK

U2 - 10.1128/JCM.42.12.5715-5721.2004

DO - 10.1128/JCM.42.12.5715-5721.2004

M3 - Article

VL - 42

SP - 5715

EP - 5721

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 12

ER -